Rockefeller Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$26.5K Sell
13,098
-114
-0.9% -$315 ﹤0.01% 3777
2026
Q2
$34.2K Sell
13,212
-4,882
-27% -$14.4K ﹤0.01% 3530
2026
Q1
$55.5K Buy
18,094
+10,542
+140% +$45.7K ﹤0.01% 3222
2025
Q4
$26.9K Buy
7,552
+152
+2% +$931 ﹤0.01% 3369
2025
Q3
$65.9K Buy
+7,400
New +$75.1K ﹤0.01% 2774
2023
Q1
– Sell
-2,700
Closed -$25K – 2120
2022
Q4
$25K Hold
2,700
– – ﹤0.01% 2708
2022
Q3
$27K Hold
2,700
– – ﹤0.01% 2636
2022
Q2
$27K Hold
2,700
– – ﹤0.01% 2566
2022
Q1
$33K Buy
2,700
+1,500
+125% +$18.4K ﹤0.01% 2494
2021
Q4
$20K Hold
1,200
– – ﹤0.01% 2638
2021
Q3
$21K Buy
1,200
+400
+50% +$7.96K ﹤0.01% 2555
2021
Q2
$18K Buy
800
+300
+60% +$4.44K ﹤0.01% 2518
2021
Q1
$7K Buy
+500
New +$5.46K ﹤0.01% 2729

Other funds holding AVXL

Rockefeller Capital Management's AVXL Position: Q3 2026 in Review

Rockefeller Capital Management reduced its Anavex Life Sciences (AVXL) stake by 0.86% in Q3 2026, selling an estimated $315 and leaving 13,098 shares worth $26.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3777.

Rockefeller Capital Management first reported a position in AVXL in Q1 2021 and has held it in 13 quarters since. The position peaked at $65.9K in Q3 2025. 165 funds tracked by Wall St. Rank hold AVXL as of Q3 2026.

  • Rockefeller Capital Management held 13,098 shares of Anavex Life Sciences worth $26.5K as of Q3 2026.
  • Rockefeller Capital Management sold 114 Anavex Life Sciences shares in Q3 2026, an estimated $315.
  • Anavex Life Sciences made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3777 holding.
  • Rockefeller Capital Management first reported a position in Anavex Life Sciences in Q1 2021 and has held it in 13 quarters since.
  • Rockefeller Capital Management's Anavex Life Sciences position peaked at $65.9K in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.